



ASX Announcement

SEPTEMBER 2019 QUARTERLY UPDATE AND APPENDIX 4C

30 October 2019 – Minneapolis, United States – Imricor Medical Systems, Inc. (Company or Imricor) (ASX:IMR) today released its Appendix 4C Quarterly Cash Flow Report for the period ended 30 September 2019.

September 2019 Quarter Cash Flow

Following its successful initial public offering, Imricor ended the quarter with significant cash reserves. Total cash and cash equivalents at 30 September 2019 were US\$7.8m, compared to US\$1.7m at 30 June 2019. The cash balance at 30 September 2019 was consistent with the prospectus estimate as the decrease in revenue associated with the delay in CE Mark versus the prospectus estimate was largely offset by decreased accounts receivable, inventory and operating expense spending.

Receipts from customers for the quarter were US\$.2m (Year to Date: US\$.3m) and primarily represented contract receipts. Operating cash payments for the quarter were US\$1.84m (Year to Date: US\$4.65m). These cash payments largely reflected staffing and other operating costs and marketing, as well as recurring costs associated with Imricor's listing on the Australian Securities Exchange. The September quarter financing cash payments was impacted by a number of one-off costs associated with the Company's Initial Public Offering.

Commenting on the quarterly Cash Flow Report, Imricor Chair and CEO, Steve Wedan, said "Following our successful IPO, Imricor is well placed to accommodate the delayed CE Mark process. We expect to provide updated guidance to the market in respect of full-year earnings expectations once the CE Mark is received. In terms of the current December quarter cash flows, they will be largely dependent on the timing of CE Mark certification which, as previously advised, we expect to receive in the near future."

Investor Conference Call

The Company will host an investor conference call today at 9:00am Australian Eastern Daylight Time (5:00pm Wednesday, 30 October USA Minneapolis, MN) with Steve Wedan, Chair and CEO and Lori Milbrandt, CFO.

To register for the call, please follow this link:

<https://zoom.us/meeting/register/471bb50369ba06adc5b9141539e44ee6>

After registering, you will receive a confirmation email containing information about joining the meeting.

ENDS

Further Information

Lori Milbrandt

Chief Financial Officer

Email: lori.milbrandt@imricor.com

Steve Wedan

Executive Chair, President, and CEO

Email: steve.wedan@imricor.com



About Imricor

Imricor Medical Systems, Inc. (ASX:IMR) is a leading developer of innovative MRI-compatible medical devices which can be used to carry out MRI-guided cardiac catheter ablation procedures. Headquartered in the US, Imricor seeks to make a meaningful impact on patients, healthcare professionals, and healthcare facilities around the world by increasing the success rates and bringing down the overall costs of cardiac catheter ablation procedures.

Foreign Ownership Restrictions

Imricor's CHES Depository Interests (**CDIs**) are issued in reliance on the exemption from registration contained in Regulation S of the US Securities Act of 1933 (**Securities Act**) for offers which are made outside the US. Accordingly, the CDIs have not been, and will not be, registered under the Securities Act or the laws of any state or other jurisdiction in the US. As a result of relying on the Regulation S exemption, the CDIs are 'restricted securities' under Rule 144 of the Securities Act. This means that you are unable to sell the CDIs into the US or to a US person for the foreseeable future except in very limited circumstances after the expiration of a restricted period, unless the re-sale of the CDIs is registered under the Securities Act or an exemption is available. To enforce the above transfer restrictions, all CDIs issued bear a 'FOR US' designation on the Australian Securities Exchange (**ASX**). This designation restricts any CDIs from being sold on ASX to US persons. However, you are still able to freely transfer your CDIs on ASX to any person other than a US person. In addition, hedging transactions with regard to the CDIs may only be conducted in accordance with the Securities Act.

Forward-Looking Statements

This announcement contains or may contain forward-looking statements that are based on the Company's management's beliefs, assumptions and expectations and on information currently available to management. All statements that address operating performance, events or developments that we expect or anticipate will occur in the future are forward-looking statements. These include, without limitation, EU commercial market acceptance and EU sales of our product as well as our expectations with respect to our ability to develop and commercialise new products. Management believes that these forward-looking statements are reasonable when made. You should not place undue reliance on forward-looking statements because they speak only as of the date when made. Imricor does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. Imricor may not actually achieve the plans, projections or expectations disclosed in forward-looking statements. Actual results, developments or events could differ materially from those disclosed in the forward-looking statements.

For personal use only

Appendix 4C

Quarterly report for entities subject to Listing Rule 4.7B

Introduced 31/03/00 Amended 30/09/01, 24/10/05, 17/12/10, 01/09/16

Name of entity

Imricor Medical Systems, Inc.

ARBN

633 106 019

Quarter ended ("current quarter")

September 30, 2019

Consolidated statement of cash flows	Current quarter \$'000 USD	Year to date 9 months \$'000 USD
1. Cash flows from operating activities		
1.1 Receipts from customers	249	319
1.2 Payments for		
(a) research and development	(229)	(635)
(b) product manufacturing and operating costs	(147)	(297)
(c) advertising and marketing	(33)	(103)
(d) leased assets	-	-
(e) staff costs	(882)	(2,574)
(f) administration and corporate costs	(474)	(858)
1.3 Dividends received (see note 3)	-	-
1.4 Interest received	11	14
1.5 Interest and other costs of finance paid	(87)	(191)
1.6 Income taxes paid	-	(1)
1.7 Government grants and tax incentives	-	-
1.8 Other (provide details if material)	-	-
1.9 Net cash from / (used in) operating activities	(1,592)	(4,326)

2. Cash flows from investing activities		
2.1 Payments to acquire:		
(a) property, plant and equipment	(131)	(490)
(b) businesses (see item 10)	-	-
(c) investments	-	-

For personal use only

Consolidated statement of cash flows	Current quarter \$'000 USD	Year to date 9 months \$'000 USD
(d) intellectual property	(55)	(103)
(e) other non-current assets	-	-
2.2 Proceeds from disposal of:		
(a) property, plant and equipment	-	-
(b) businesses (see item 10)	-	-
(c) investments	-	-
(d) intellectual property	-	-
(e) other non-current assets	-	-
2.3 Cash flows from loans to other entities	-	-
2.4 Dividends received (see note 3)	-	-
2.5 Other (provide details if material)	-	-
2.6 Net cash from / (used in) investing activities	(186)	(593)

3. Cash flows from financing activities		
3.1 Proceeds from issues of shares	8,768	8,768
3.2 Proceeds from issue of convertible notes	-	1,746
3.3 Proceeds from exercise of share options	-	176
3.4 Transaction costs related to issues of shares, convertible notes or options	(886)	(1,149)
3.5 Proceeds from borrowings	-	1,700
3.6 Repayment of borrowings	(77)	(132)
3.7 Transaction costs related to loans and borrowings	-	-
3.8 Dividends paid	-	-
3.9 Other (provide details if material)	-	-
3.10 Net cash from / (used in) financing activities	7,805	11,109

4. Net increase / (decrease) in cash and cash equivalents for the period		
4.1 Cash and cash equivalents at beginning of quarter/year to date	1,743	1,588
4.2 Net cash from / (used in) operating activities (item 1.9 above)	(1,592)	(4,326)
4.3 Net cash from / (used in) investing activities (item 2.6 above)	(186)	(593)
4.4 Net cash from / (used in) financing activities (item 3.10 above)	7,805	11,109

Consolidated statement of cash flows		Current quarter \$'000 USD	Year to date 9 months \$'000 USD
4.5	Effect of movement in exchange rates on cash held	9	1
4.6	Cash and cash equivalents at end of quarter	7,779	7,779

5.	Reconciliation of cash and cash equivalents at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts	Current quarter \$'000 USD	Previous quarter \$'000 USD
5.1	Bank balances	7,779	7,779
5.2	Call deposits	-	-
5.3	Bank overdrafts	-	-
5.4	Other (provide details)	-	-
5.5	Cash and cash equivalents at end of quarter (should equal item 4.6 above)	7,779	7,779

6. Payments to directors of the entity and their associates**Current quarter
\$'000 USD**

6.1 Aggregate amount of payments to these parties included in item 1.2

-

6.2 Aggregate amount of cash flow from loans to these parties included in item 2.3

-

6.3 Include below any explanation necessary to understand the transactions included in items 6.1 and 6.2

7. Payments to related entities of the entity and their associates**Current quarter
\$'000 USD**

7.1 Aggregate amount of payments to these parties included in item 1.2

-

7.2 Aggregate amount of cash flow from loans to these parties included in item 2.3

-

7.3 Include below any explanation necessary to understand the transactions included in items 7.1 and 7.2

8. Financing facilities available <i>Add notes as necessary for an understanding of the position</i>	Total facility amount at quarter end \$'000 USD	Amount drawn at quarter end \$'000 USD
8.1 Loan facilities	-	-
8.2 Credit standby arrangements	-	-
8.3 Other (please specify)	-	-
8.4 Include below a description of each facility above, including the lender, interest rate and whether it is secured or unsecured. If any additional facilities have been entered into or are proposed to be entered into after quarter end, include details of those facilities as well.		


9. Estimated cash outflows for next quarter	\$'000 USD
9.1 Research and development	(358)
9.2 Product manufacturing and operating costs	(859)
9.3 Advertising and marketing	(105)
9.4 Leased assets	-
9.5 Staff costs	(1,310)
9.6 Administration and corporate costs	(552)
9.7 Other (provide details if material)	-
9.8 Total estimated cash outflows	(3,184)

10. Acquisitions and disposals of business entities (items 2.1(b) and 2.2(b) above)	Acquisitions	Disposals
10.1 Name of entity	n/a	n/a
10.2 Place of incorporation or registration	n/a	n/a
10.3 Consideration for acquisition or disposal	n/a	n/a
10.4 Total net assets	n/a	n/a
10.5 Nature of business	n/a	n/a

For personal use only

Compliance statement

- 1 This statement has been prepared in accordance with accounting standards and policies which comply with Listing Rule 19.11A.
- 2 This statement gives a true and fair view of the matters disclosed.

Sign here: 
(Director)

Date: 31 October 2019

Print name: Steve Wedan

Notes

1. The quarterly report provides a basis for informing the market how the entity's activities have been financed for the past quarter and the effect on its cash position. An entity that wishes to disclose additional information is encouraged to do so, in a note or notes included in or attached to this report.
2. If this quarterly report has been prepared in accordance with Australian Accounting Standards, the definitions in, and provisions of, *AASB 107: Statement of Cash Flows* apply to this report. If this quarterly report has been prepared in accordance with other accounting standards agreed by ASX pursuant to Listing Rule 19.11A, the corresponding equivalent standard applies to this report.
3. Dividends received may be classified either as cash flows from operating activities or cash flows from investing activities, depending on the accounting policy of the entity.